Clinical Trial

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Funding Source - FDA OOPD
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2016-11-16; most recent amendment 2026-05-05.
Status change: Recruiting → Active, Not Recruiting 2024-12-16
Status change: Not Yet Recruiting → Recruiting 2017-06-28
Trial Details
NCT Number NCT02968212
Lead Sponsor Oregon Health and Science University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), National Jewish Health, The University of Texas Health Science Center at Tyler, National Institute of Allergy and Infectious Diseases (NIAID), University of Chicago, Temple University, University of South Florida
Conditions Mycobacterium Avium Complex
Enrollment 102 participants
Start Date 2017-04-11
Primary Completion 2025-08-29 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-06